ライフサイエンスコーパス: reverse transcriptase inhibitor

1 e transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors).

2 tase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor.

3 ncoming viral RNAs even in the presence of a reverse transcriptase inhibitor.

4 on a first-generation nonnucleoside analogue reverse transcriptase inhibitor.

5 4-5.9]); all mutations were to nonnucleoside reverse transcriptase inhibitors.

6 viously described for the IAS non-nucleoside reverse transcriptase inhibitors.

7 ved 400 mg RAL twice daily plus 2 nucleoside reverse transcriptase inhibitors.

8 ders viral resistance to multiple nucleoside reverse transcriptase inhibitors.

9 late the prophylactic efficacy of nucleotide reverse transcriptase inhibitors.

10 ing of at least two nucleoside or nucleotide reverse transcriptase inhibitors.

11 without evidence of resistance to nucleoside reverse transcriptase inhibitors.

12 ict PrEP potency for all drug classes except reverse transcriptase inhibitors.

13 rs (PI) with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.

14 l antiretroviral therapy with two nucleoside reverse transcriptase inhibitors.

15 he DNA-DSB site, and TSIs were suppressed by reverse-transcriptase inhibitors.

16 e-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors.

17 iation (0.71 [0.61-0.82]) and non-nucleoside reverse transcriptase inhibitor (0.68 [0.51-0.90]) or in

18 of two pyrimidine-based HIV-1 non-nucleoside reverse transcriptase inhibitors, 1 (MC1501) and 2 (MC20

19 inhibitor-based regimens (vs non-nucleoside reverse transcriptase inhibitor; 1.17, 1.00-1.36).

20 Quantification of 6 nucleoside/nucleotide reverse transcriptase inhibitors, 2 non-nucleoside rever

21 eekly CD4 counts and to receive 2 nucleoside reverse transcriptase inhibitors (2NRTI, mainly abacavir

22 on for NNRTIs (5.4%), followed by nucleoside reverse transcriptase inhibitors (3.0%) and protease inh

23 Treatment with the reverse transcriptase inhibitor 3TC resulted in decrease

24 criptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integra

25 ommon 3DR was dolutegravir plus 2 nucleoside reverse transcriptase inhibitors (46.9%).

26 e transcriptase inhibitors, 2 non-nucleoside reverse transcriptase inhibitors, 7 protease inhibitors,

27 o major mutations (3% vs 51%), nonnucleoside reverse transcriptase inhibitor (94% vs 44%), M184V/I (9

28 larly in the quantification of nonnucleoside reverse transcriptase inhibitor and lamivudine mutations

29 newer PIs, second-generation non-nucleoside reverse transcriptase inhibitors and drugs in novel clas

30 Nonnucleoside reverse transcriptase inhibitors and integrase inhibitor

31 in the cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integrase inhibitor

32 ce; 1 EFV, emergent resistance to nucleoside reverse transcriptase inhibitors and nonnucleoside rever

33 ations increased resistance to nonnucleoside reverse transcriptase inhibitors and vice versa.

34 This survey classified nonnucleoside reverse-transcriptase inhibitor and nucleoside reverse-t

35 Nine nucleoside reverse-transcriptase inhibitors and 37 nucleoside/heter

36 ied as moderate (5%-15%) for both nucleoside reverse-transcriptase inhibitors and nonnucleoside rever

37 ther multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-booste

38 resistance, background regimen of nucleoside reverse-transcriptase inhibitors, and the standard ramp-

39 reverse transcriptase inhibitor-, nucleoside reverse transcriptase inhibitor-, and protease inhibitor

40 our detection specificity with the use of a reverse transcriptase inhibitor as a counterscreen, enab

41 ntification of thymidine analogue nucleoside reverse transcriptase inhibitors as the cause of lipoatr

42 core </=2 in 10 patients included nucleoside reverse transcriptase inhibitors associated with darunav

43 imilar proportions of overall and nucleoside reverse transcriptase inhibitor-associated minority vari

44 ipant in the atazanavir group had nucleoside reverse transcriptase inhibitor-associated resistance th

45 To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral ne

46 e implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity.

47 he clinically administered nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT).

48 constructs in the presence or absence of the reverse-transcriptase inhibitor azidothymidine.

49 Remarkably, reverse transcriptase inhibitor AZT-treated Chk2 mutant

50 of virologic failure with either nucleoside reverse transcriptase inhibitor backbone than women assi

51 a boosted darunavir regimen with nucleoside reverse transcriptase inhibitor background treatment for

52 A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-a

53 Nonnucleoside reverse transcriptase inhibitor-based antiretroviral the

54 lopinavir/ritonavir (LPV/r) or nonnucleoside reverse transcriptase inhibitor-based ART and treated wi

55 only individuals on first-line nonnucleoside reverse transcriptase inhibitor-based ART regimens.

56 1.01-1.07), being prescribed non-nucleoside reverse transcriptase inhibitor-based regimens (1.63, 1.

57 nce interval [CI], 90%-99.7%); nonnucleoside reverse transcriptase inhibitor-based, 100% (95% CI, 91%

58 use of a tenofovir-containing nonnucleoside reverse-transcriptase inhibitor-based first-line regimen

59 -62]; P = .001), compared with nonnucleoside reverse-transcriptase inhibitor-based regimens.

60 Antihepadnaviral treatment using an approved reverse transcriptase inhibitor blocked replication of a

61 dence that telomerase can add the nucleotide reverse transcriptase inhibitors ddITP and AZT-TP to the

62 localization of LysRS, but treatment with a reverse transcriptase inhibitor does not, suggesting tha

63 AS, or treatment of MAVS-deficient mice with reverse transcriptase inhibitors, dramatically inhibits

64 For non-nucleotide reverse transcriptase inhibitor DRMs, sensitivity and sp

65 For nucleotide reverse transcriptase inhibitor DRMs, sensitivity and sp

66 %) levels of resistance to the nonnucleoside reverse transcriptase inhibitor drug class.

67 No individual ARV in the reverse transcriptase inhibitor drug classes was associa

68 tance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identifie

69 eiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpiviri

70 vitegravir, or raltegravir), a nonnucleoside reverse transcriptase inhibitor (efavirenz or rilpivirin

71 or abacavir/lamivudine) plus a nonnucleoside reverse transcriptase inhibitor (efavirenz), a ritonavir

72 We further show that the addition of reverse transcriptase inhibitors effectively suppresses

73 ART regimens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boos

74 , both with investigator-selected nucleoside reverse transcriptase inhibitors: emtricitabine and teno

75 Receipt of nucleoside reverse-transcriptase inhibitors, especially stavudine a

76 Resistance to the nonnucleoside reverse transcriptase inhibitors etravirine and rilpivir

77 Transplacental nucleoside reverse-transcriptase inhibitor exposures induced fetal

78 rhesus macaques with protease, integrase, or reverse transcriptase inhibitors for 1 to 2 or for 5 to

79 virenz (EFV; 600 mg daily) with 2 nucleoside reverse transcriptase inhibitors for 52 weeks.

80 infants received ineffective non-nucleoside reverse transcriptase inhibitors for PMTCT.

81 -retroviral therapy with multiple nucleoside reverse transcriptase inhibitors for the treatment of pa

82 n inhibitor (PIE12-Trimer), a combination of reverse transcriptase inhibitors (FTC-TDF), a thioester

83 n that combined nucleoside and nonnucleoside reverse-transcriptase inhibitors (hereafter, "NNRTI stra

84 bserved with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying abacavir a

85 anscriptase inhibitors in 62%, nonnucleoside reverse transcriptase inhibitors in 57%, protease inhibi

86 9 youth, identified resistance to nucleoside reverse transcriptase inhibitors in 62%, nonnucleoside r

87 sted proteasome inhibitors and nonnucleotide reverse transcriptase inhibitors in the cART regimen, in

88 pregnancy, 1 of which was without nucleoside reverse transcriptase inhibitors, infants had a specific

89 these new features with a simple case (HIV-1 reverse transcriptase/inhibitor interaction) and with th

90 ontaining dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between

91 The antiviral activity of nucleoside reverse transcriptase inhibitors is often hampered by in

92 as 2-LTR quantification and the addition of reverse transcriptase inhibitors, is crucial to fully el

93 Nonnucleoside reverse transcriptase inhibitor (K103N, V106M, Y181C, an

94 Treatment of aged mice with the nucleoside reverse transcriptase inhibitor lamivudine downregulated

95 resistance to the co-administered nucleoside reverse transcriptase inhibitors might reduce effectiven

96 e (RPV) and EFV plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) in treatment

97 h common background nucleoside or nucleotide reverse transcriptase inhibitors (N[t]RTIs).

98 In addition, treatment with the reverse transcriptase inhibitor nevirapine delayed uncoa

99 The nonnucleoside reverse transcriptase inhibitor nevirapine is the corner

100 lopinavir and saquinavir, the nonnucleoside reverse-transcriptase inhibitor nevirapine, and the anti

101 (darunavir, atazanavir), and 2 nonnucleoside reverse transcriptase inhibitors (nevirapine, efavirenz)

102 avirenz is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) and a common com

103 luated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103

104 The non-nucleoside reverse transcriptase inhibitor (NNRTI) based FDC of ril

105 "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site.

106 led RT in the presence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV)

107 ated that a formulation of the nonnucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 in carra

108 mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%)

109 y abacavir+lamivudine) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 3 NRTIs as lo

110 psychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a

111 antiretroviral therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two NRTIs h

112 eficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutat

113 ttributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance.

114 e risk factors associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.

115 The non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278/rilpiviri

116 The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TM

117 leoside human immunodeficiency virus (HIV)-1 reverse transcriptase inhibitor (NNRTI), was safe and ef

118 mg every 48 hours as part of a nonnucleoside reverse transcriptase inhibitor (NNRTI)- or lopinavir/ri

119 protease inhibitor (PI)-, and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART betwee

120 Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly act

121 n protease inhibitor (PI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens w

122 rologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens.

123 Non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutant

124 e inhibitor and superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI).

125 irus type 1 (HIV-1) by a novel nonnucleoside reverse transcriptase inhibitor (NNRTI).

126 ne/efavirenz, presence of both nonnucleoside reverse transcriptase inhibitor (NNRTI)/nucleoside rever

127 ) or on a regimen containing a nonnucleoside reverse transcriptase inhibitor (NNRTI; N = 52) or prote

128 dine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or ef

129 of alkenyldiarylmethane (ADAM) nonnucleoside reverse transcriptase inhibitors (NNRTI) 3 and 4 with HI

130 ountries are moving away from non-nucleoside reverse transcriptase inhibitors (NNRTI) and transitioni

131 tice regarding the use of the non-nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (EFV)

132 al increases in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) in east Africa

133 New non-nucleoside reverse transcriptase inhibitors (NNRTI), which are simi

134 n than protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTI), with dolutegra

135 aluated the impact of several non-nucleoside reverse transcriptase inhibitors (NNRTI; Efavirenz, Etra

136 table markedly faster than did nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations (hazar

137 ed patients failing an initial nonnucleoside reverse-transcriptase inhibitor (NNRTI) regimen in Afric

138 over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in pe

139 or (NRTI) resistance, 9.8% had nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, and

140 Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active again

141 llows: exposure to nonstandard nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based (hazard ra

142 RT) than among those receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART.

143 ing of ART as a change from a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen to

144 patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy su

145 ling therapy on a TDF/XTC plus nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regim

146 We sought to detect minor nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant varian

147 ffect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant varian

148 40%), boosted ARVs (30%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (32%) based re

149 riptase inhibitors (NRTIs), 4 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 2 protease

150 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent and

151 Although nonnucleoside reverse transcriptase inhibitors (NNRTIs) are usually pa

152 Worldwide, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and

153 riptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) has been assoc

154 he prevalence of resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) have been obse

155 Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent

156 Increased use of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in pregnant an

157 lence levels of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) measured in th

158 iral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromi

159 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) play a central

160 e prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (9

161 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) that target th

162 Rising resistance of HIV-1 to non-nucleoside reverse transcriptase inhibitors (NNRTIs) threatens the

163 ation of a clinical candidate non-nucleoside reverse transcriptase inhibitors (NNRTIs) with a novel a

164 nscriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease

165 (1H)-ones were synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs), and their bio

166 nd tallied major mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside re

167 itted drug resistance (TDR) to nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside re

168 , is influenced by mutations, non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide su

169 an were protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs), with dolutegr

170 ithin the class of allosteric non-nucleoside reverse transcriptase inhibitors (NNRTIs).

171 mainly driven by resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).

172 Moderate (5%-15%) TDR to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) was observed a

173 riptase inhibitors [NRTIs] and nonnucleoside reverse transcriptase inhibitors [NNRTIs]), integrase st

174 in patients receiving PIs and nonnucleoside reverse transcriptase inhibitors [NNRTIs], and 60.3% [P

175 Here, we assessed the ability of nucleoside reverse-transcriptase inhibitor/nonnucleoside reverse-tr

176 ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among th

177 fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone with lam

178 il fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone.

179 iated ART consisting of different nucleoside reverse transcriptase inhibitor (NRTI) backbones (zidovu

180 ns (47% vs 18%), all P = .01; and nucleoside reverse transcriptase inhibitor (NRTI) cross-resistance

181 MS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maint

182 SPNs) of the highly water-soluble nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (FT

183 ine or emtricitabine plus another nucleoside reverse transcriptase inhibitor (NRTI) in fixed-dose com

184 apy (ART) for HIV patients is the nucleoside reverse transcriptase inhibitor (NRTI) is tenofovir.

185 of greater emergence of the K65R nucleoside reverse transcriptase inhibitor (NRTI) mutation in human

186 t frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%),

187 individuals; 15.8% had nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, 9.8%

188 Sixteen nucleoside reverse transcriptase inhibitor (NRTI) SDRMs accounted f

189 00 or >100,000 copies per mL) and nucleoside reverse transcriptase inhibitor (NRTI) selection.

190 n ART, and 20 (6.8%) started dual nucleoside reverse transcriptase inhibitor (NRTI) therapy.

191 S-p53 cells were treated with the nucleoside reverse transcriptase inhibitor (NRTI), 2',3'-dideoxycyt

192 , HIV-positive patients receiving nucleoside reverse transcriptase inhibitor (NRTI)-based ART, and HI

193 We hypothesized that nucleos(t)ide reverse transcriptase inhibitors (NRTI) may contribute t

194 Nucleoside reverse transcriptase inhibitors (NRTI) require intracel

195 inhibitor mutations; 41 (91%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations; 33 (73

196 mmon ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleosid

197 namics of emerging nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI) resistance in hep

198 V) alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)-sparing benefits,

199 Nucleoside reverse-transcriptase inhibitors (NRTI), drugs approved

200 , zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group) or lopinav

201 o two classes: nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs).

202 l resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs).

203 18 years who started ART with two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucle

204 first-line regimen of PI/r plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) and had at leas

205 Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs a

206 development of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleosi

207 Nucleoside reverse transcriptase inhibitors (NRTIs) are mainstay th

208 Nucleoside reverse transcriptase inhibitors (NRTIs) are often inclu

209 ministered with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended

210 Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essenti

211 Nucleoside reverse transcriptase inhibitors (NRTIs) are widely used

212 of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely o

213 irenz 600 mg once a day with dual nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks of

214 (Ed4T), have been investigated as nucleoside reverse transcriptase inhibitors (NRTIs) for treatment o

215 navir-boosted lopinavir, plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults in wh

216 the potency of nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) is an important

217 opinavir, and atazanavir) but not nucleoside reverse transcriptase inhibitors (NRTIs) or nonnucleosid

218 regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integra

219 taggered interruption, whereby nucleos(t)ide reverse transcriptase inhibitors (NRTIs) were continued

220 Nucleoside reverse transcriptase inhibitors (NRTIs) were the first

221 Nucleoside reverse transcriptase inhibitors (NRTIs) with L-stereoch

222 ranscriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease i

223 ranscriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease i

224 ization method to classify TDR to nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside

225 Because nucleoside reverse transcriptase inhibitors (NRTIs), the most commo

226 ease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs).

227 f the same resistance pathways to nucleoside reverse transcriptase inhibitors (NRTIs).

228 mended initial regimens include 2 nucleoside reverse transcriptase inhibitors (NRTIs; abacavir/lamivu

229 The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain w

230 o paediatric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in first-line a

231 is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line

232 The effect of nonthymidine nucleoside reverse-transcriptase inhibitors (NRTIs) on fat mitochon

233 ndard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line com

234 The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucle

235 Subjects received nucleoside or nucleotide reverse-transcriptase inhibitors (NRTIs) with or without

236 o 12 HIV-1 inhibitors including 6 nucleoside reverse-transcriptase inhibitors (NRTIs), 4 non-nucleosi

237 r, with adjustment of one or more nucleoside reverse-transcriptase inhibitors (NRTIs).

238 sets of mutations in response to nucleoside reverse-transcriptase inhibitors (NRTIs).

239 reverse transcriptase inhibitors (nucleoside reverse transcriptase inhibitors [NRTIs] and nonnucleosi

240 and cohorts B (B1, best available nucleoside reverse transcriptase inhibitors [NRTIs] plus ritonavir-

241 y associated with a nucleoside or nucleotide reverse transcriptase inhibitor (NtRTI)-sparing regimen.

242 ease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compr

243 ection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these dru

244 ated with resistance to protease inhibitors, reverse transcriptase inhibitors (nucleoside reverse tra

245 o against wild-type HIV-1 and non-nucleoside reverse transcriptase inhibitor-, nucleoside reverse tra

246 Here we analyzed whether abacavir, an HIV-1 reverse transcriptase inhibitor often inducing severe de

247 We evaluated the effects of nucleoside reverse-transcriptase inhibitors on leukocyte-endotheliu

248 her effective regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inh

249 d first-line regimens based on nonnucleoside reverse transcriptase inhibitors or integrase inhibitors

250 tase inhibitors (NRTIs) with a nonnucleoside reverse-transcriptase inhibitor or a ritonavir-boosted p

251 therapy (ART) with at least 1 nonnucleoside reverse-transcriptase inhibitor or protease inhibitor.

252 but not among mothers who used nonnucleoside reverse-transcriptase inhibitor or triple-nucleoside reg

253 RNA from HIV-1-infected cells treated with a reverse-transcriptase inhibitor or with heat-inactivated

254 e transcriptase inhibitor (NNRTI)/nucleoside reverse transcriptase inhibitor PDR vs no PDR was associ

255 of a first-line regimen of a non-nucleoside reverse transcriptase inhibitor plus two NtRTIs.

256 ical responses to cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-booste

257 The regimen consisted of two nucleoside reverse transcriptase inhibitors plus nevirapine dosed a

258 criptase inhibitors (NRTIs) or nonnucleoside reverse transcriptase inhibitors reduced trophoblast pro

259 0 copies/mL, and 79% were on a nonnucleoside reverse transcriptase inhibitor regimen.

260 In this model, reverse-transcriptase inhibitors rescued the neurotoxici

261 e (63%) of eight had archived non-nucleoside reverse transcriptase inhibitor resistance-associated mu

262 icipants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations wer

263 Nucleoside reverse-transcriptase inhibitor resistance pathways in H

264 resistance to 1 or more NNRTI or nucleoside reverse transcriptase inhibitors, respectively.

265 two decades since the approval of the first reverse transcriptase inhibitor (retrovir, GlaxoSmithKli

266 long-acting formulation of the nonnucleoside reverse transcriptase inhibitor rilpivirine (RPV LA) has

267 , and in combination with the non-nucleoside reverse transcriptase inhibitor rilpivirine.

268 eened the efficacy of commercially available reverse transcriptase inhibitors (RTIs) at inhibiting th

269 ested to be a major substrate for TREX1, and reverse transcriptase inhibitors (RTIs) were proposed as

270 the host cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candi

271 ld-type HIV-1 strains and those resistant to reverse transcriptase inhibitors (RTIs).

272 ofile, which support its use as a nucleoside reverse transcriptase inhibitor-sparing and protease inh

273 -1 transmission and/or for use in nucleoside reverse transcriptase inhibitor-sparing antiretroviral r

274 ase inhibitors, nonnucleoside and nucleotide reverse transcriptase inhibitors TDR mutations, namely,

275 fidence interval, 0.07%-13.8%) nonnucleoside reverse-transcriptase inhibitor TDR was determined.

276 nhibitor (PI) lopinavir (LPV) and nucleoside reverse transcriptase inhibitor tenofovir alafenamide (T

277 ntly dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigt

278 enofovir alafenamide delivers the nucleotide reverse transcriptase inhibitor tenofovir to target cell

279 erapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.

280 mended initial regimens include 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabin

281 We evaluated two long-acting reverse transcriptase inhibitors, tenofovir (TFV) and em

282 Among nucleoside/nucleotide reverse transcriptase inhibitors, tenofovir alafenamide

283 Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-infer

284 etroviral medications, such as nonnucleoside reverse transcriptase inhibitors, the detection of these

285 the mechanisms by which nucleoside-analogue reverse transcriptase inhibitors, the most common class

286 ularly among those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior to combina

287 RNA concentration and background nucleoside reverse transcriptase inhibitor therapy, to doravirine (

288 elucidate potential mechanisms of nucleoside reverse-transcriptase inhibitor toxicities.

289 verse-transcriptase inhibitor and nucleoside reverse-transcriptase inhibitor transmitted drug resista

290 everse-transcriptase inhibitor/nonnucleoside reverse-transcriptase inhibitor treatment to restore the

291 Non-nucleotide reverse transcriptase inhibitor use was associated with

292 ociations between single and dual nucleoside reverse-transcriptase inhibitor use and possible mitocho

293 rdiovascular (CV) toxicity of the nucleoside reverse-transcriptase inhibitors used to treat human imm

294 Baseline drug resistance to nucleoside reverse transcriptase inhibitors was observed in 54.5% o

295 uring antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associat

296 Relevant mutations affecting nonnucleoside reverse transcriptase inhibitors were found in 32 of 133

297 d efavirenz, were open-label; the nucleoside reverse transcriptase inhibitors were prematurely unblin

298 Nucleotide-competing reverse transcriptase inhibitors were shown to bind reve

299 e or peptide scaffolds containing nucleoside reverse transcriptase inhibitors were synthesized.

300 Non-nucleoside reverse-transcriptase inhibitors, zidovudine, and didano